Immune thrombocytopenic purpura (ITP) refers to a rare autoimmune disorder in which the body's immune system destroys the blood cells that help in blood clotting (platelets). In the United States, the incidence of this disease is around 66 cases per 1,000,000 every year in adults. Treatments such as corticosteroids, immunoglobulins, and thrombopoietin receptor agonists (TPO-RAs) are available in the market. However, a substantial portion of the patient population fails to achieve sustained remission. Recent advancements in the treatment landscape are likely to introduce several promising immune thrombocytopenic purpura drugs in the coming years.
The Immune Thrombocytopenic Purpura Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into immune thrombocytopenic purpura therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for immune thrombocytopenic purpura. The immune thrombocytopenic purpura report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The immune thrombocytopenic purpura pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with immune thrombocytopenic purpura treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to immune thrombocytopenic purpura.
Immune thrombocytopenic purpura is an autoimmune disorder characterized by low platelet counts, leading to an increased risk of bleeding. It can be acute (short-term) or chronic (long-term). Acute immune thrombocytopenic purpura is reported as the most common form and typically affects children whereas chronic form of the disease mostly affects adults.
Common immune thrombocytopenic purpura therapeutics include corticosteroids such as prednisone and dexamethasone that work by suppressing immune activity and increasing platelet counts. Intravenous immunoglobulin (IVIg) is another first-line treatment that temporarily increases platelet counts by modulating the immune response. Advancements in ITP therapeutics, coupled with evidence-based immune thrombocytopenic purpura treatment guidelines, are anticipated to improve patient outcomes and support pipeline expansion.
Recent epidemiological studies reveal an average estimate of immune thrombocytopenic purpura incidence to be 50 cases per 1,000,000 in children and 66 cases per 1,000,000 in adults each year in the United States. Further, new cases of chronic refractory immune thrombocytopenic purpura are estimated to be 10 cases per 1,000,000 annually in the region.
As per the studies conducted in England and Denmark, childhood immune thrombocytopenic purpura occurs in about 10 to 40 cases per 1,000,000 each year.
This section of the report covers the analysis of immune thrombocytopenic purpura drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of Immune Thrombocytopenic Purpura emerging drugs undergoing clinical development.
The drug molecule categories covered under immune thrombocytopenic purpura pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The immune thrombocytopenic purpura report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for immune thrombocytopenic purpura.
The EMR report for immune thrombocytopenic purpura drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed immune thrombocytopenic purpura therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in immune thrombocytopenic purpura clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by argenx, the objective of this multicenter, randomized, double-blinded clinical trial is to investigate the efficacy and safety of immune thrombocytopenic purpura drug candidate Efgartigimod IV for the treatment of primary immune thrombocytopenia in adult patients. The study is under Phase III clinical development and has an estimated 63 participants.
Principia Biopharma, a Sanofi Company, is conducting a Phase II clinical trial aimed at examining the efficacy...
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The Immune Thrombocytopenic Purpura Drug Report provides a strategic overview of the latest and future landscape of treatments for immune thrombocytopenic purpura. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within immune thrombocytopenic purpura pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share